Literature DB >> 25347994

M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.

Ratanesh Kumar Seth1, Suvarthi Das1, Sahar Pourhoseini1, Diptadip Dattaroy1, Stephen Igwe1, Julie Basu Ray1, Daping Fan1, Gregory A Michelotti1, Anna Mae Diehl1, Saurabh Chatterjee2.   

Abstract

Activation of M1 macrophages in nonalcoholic steatohepatitis (NASH) is produced by several external or endogenous factors: inflammatory stimuli, oxidative stress, and cytokines are known. However, any direct role of oxidative stress in causing M1 polarization in NASH has been unclear. We hypothesized that CYP2E1-mediated oxidative stress causes M1 polarization in experimental NASH, and that nitric oxide (NO) donor administration inhibits CYP2E1-mediated inflammation with concomitant attenuation of M1 polarization. Because CYP2E1 takes center stage in these studies, we used a toxin model of NASH that uses a ligand and a substrate of CYP2E1 for inducing NASH. Subsequently, we used a methionine and choline-deficient diet-induced rodent NASH model where the role of CYP2E1 in disease progression has been shown. Our results show that CYP2E1 causes M1 polarization bias, which includes a significant increase in interleukin-1β (IL-1β) and IL-12 in both models of NASH, whereas CYP2E1-null mice or diallyl sulfide administration prevented it. Administration of gadolinium chloride (GdCl3), a macrophage toxin, attenuated both the initial M1 response and the subsequent M2 response, showing that the observed increase in cytokine levels is primarily from macrophages. Based on the evidence of an adaptive NO increase, the NO donor administration in vivo that mechanistically inhibited CYP2E1 catalyzed the oxidative stress during the entire study in NASH-abrogated M1 polarization and NASH progression. The results obtained show the association of CYP2E1 in M1 polarization, and that inhibition of CYP2E1 catalyzed oxidative stress by an NO donor (DETA NONOate [(Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate]) can be a promising therapeutic strategy in NASH.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25347994      PMCID: PMC4279102          DOI: 10.1124/jpet.114.218131

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice.

Authors:  Virginia Maina; Salvatore Sutti; Irene Locatelli; Matteo Vidali; Cristina Mombello; Cristina Bozzola; Emanuele Albano
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

2.  Fibrogenic signalling in hepatic stellate cells.

Authors:  Derek A Mann; Fabio Marra
Journal:  J Hepatol       Date:  2010-03-20       Impact factor: 25.083

Review 3.  Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.

Authors:  J Aubert; K Begriche; L Knockaert; M A Robin; B Fromenty
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-06-12       Impact factor: 2.947

4.  Arginine metabolic pathways determine its therapeutic benefit in experimental heatstroke: role of Th1/Th2 cytokine balance.

Authors:  Saurabh Chatterjee; Sudha Premachandran; Raghavendra S Bagewadikar; Sayanti Bhattacharya; Subrata Chattopadhyay; T B Poduval
Journal:  Nitric Oxide       Date:  2006-04-26       Impact factor: 4.427

5.  CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis.

Authors:  Ratanesh Kumar Seth; Suvarthi Das; Ashutosh Kumar; Anindya Chanda; Maria B Kadiiska; Gregory Michelotti; Jose Manautou; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2013-11-07       Impact factor: 4.219

6.  Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation.

Authors:  Veerle Bieghs; Sofie M A Walenbergh; Tim Hendrikx; Patrick J van Gorp; Fons Verheyen; Steven W Olde Damink; Ad A Masclee; Ger H Koek; Marten H Hofker; Christoph J Binder; Ronit Shiri-Sverdlov
Journal:  Liver Int       Date:  2013-04-25       Impact factor: 5.828

7.  Immuno-spin trapping of a post-translational carboxypeptidase B1 radical formed by a dual role of xanthine oxidase and endothelial nitric oxide synthase in acute septic mice.

Authors:  Saurabh Chatterjee; Marilyn Ehrenshaft; Suchandra Bhattacharjee; Leesa J Deterding; Marcelo G Bonini; Jean Corbett; Maria B Kadiiska; Kenneth B Tomer; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2008-11-07       Impact factor: 7.376

8.  The liver-selective nitric oxide donor O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) protects HepG2 cells against cytochrome P450 2E1-dependent toxicity.

Authors:  Pengfei Gong; Arthur I Cederbaum; Natalia Nieto
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

Review 9.  Oxidative stress, toxicology, and pharmacology of CYP2E1.

Authors:  Andres A Caro; Arthur I Cederbaum
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

Review 10.  Immune and inflammatory pathways in NASH.

Authors:  Michal Ganz; Gyongyi Szabo
Journal:  Hepatol Int       Date:  2013-08-30       Impact factor: 6.047

View more
  12 in total

Review 1.  Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.

Authors:  Mohamed A Abdelmegeed; Seung-Kwon Ha; Youngshim Choi; Mohammed Akbar; Byoung-Joon Song
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Suvarthi Das; Firas Alhasson; Varun Chandrashekaran; Gregory Michelotti; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-12-30       Impact factor: 4.052

Review 3.  Nitric oxide in liver diseases.

Authors:  Yasuko Iwakiri; Moon Young Kim
Journal:  Trends Pharmacol Sci       Date:  2015-05-28       Impact factor: 14.819

4.  TRPV4 activation of endothelial nitric oxide synthase resists nonalcoholic fatty liver disease by blocking CYP2E1-mediated redox toxicity.

Authors:  Ratanesh K Seth; Suvarthi Das; Diptadip Dattaroy; Varun Chandrashekaran; Firas Alhasson; Gregory Michelotti; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; P Darwin Bell; Wolfgang Liedtke; Saurabh Chatterjee
Journal:  Free Radic Biol Med       Date:  2016-11-29       Impact factor: 7.376

5.  The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation.

Authors:  Xiaolu Wang; Yun Gao; Juan Song; Chao Tang; Man Wang; Linli Que; Li Liu; Guoqing Zhu; Qi Chen; Yong Yao; Yong Xu; Jiantao Li; Yuehua Li
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

6.  Critical Role for Hepatocyte-Specific eNOS in NAFLD and NASH.

Authors:  Rory P Cunningham; Mary P Moore; Ryan J Dashek; Grace M Meers; Takamune Takahashi; Ryan D Sheldon; Andrew A Wheeler; Alberto Diaz-Arias; Jamal A Ibdah; Elizabeth J Parks; John P Thyfault; R Scott Rector
Journal:  Diabetes       Date:  2021-08-11       Impact factor: 9.461

7.  Intermittent hypoxia is a proinflammatory stimulus resulting in IL-6 expression and M1 macrophage polarization.

Authors:  Esperance Schaefer; Winona Wu; Christina Mark; Andrew Yang; Erik DiGiacomo; Charles Carlton-Smith; Shadi Salloum; Cynthia Brisac; Wenyu Lin; Kathleen E Corey; Raymond T Chung
Journal:  Hepatol Commun       Date:  2017-05-18

8.  Supplementation of 17β-Estradiol Normalizes Rapid Gastric Emptying by Restoring Impaired Nrf2 and nNOS Function in Obesity-Induced Diabetic Ovariectomized Mice.

Authors:  Jeremy C Sprouse; Chethan Sampath; Pandu R Gangula
Journal:  Antioxidants (Basel)       Date:  2020-07-03

9.  Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease.

Authors:  Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Ratanesh K Seth; Philip Busbee; Hasan Alghetaa; Dwayne E Porter; Geoff I Scott; Bryan Brooks; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

Review 10.  The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development.

Authors:  Rory P Cunningham; Ryan D Sheldon; R Scott Rector
Journal:  Front Physiol       Date:  2020-07-03       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.